{"id":"NCT02528188","sponsor":"Pfizer","briefTitle":"Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-21","primaryCompletion":"2018-10-05","completion":"2019-02-27","firstPosted":"2015-08-19","resultsPosted":"2020-01-10","lastUpdate":"2020-01-10"},"enrollment":3021,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain","Osteoarthritis, Hip","Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"NSAID","otherNames":[]},{"type":"BIOLOGICAL","name":"Tanezumab 2.5 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"Tanezumab 5 mg","otherNames":[]}],"arms":[{"label":"NSAID","type":"ACTIVE_COMPARATOR"},{"label":"Tanezumab 2.5 mg","type":"EXPERIMENTAL"},{"label":"Tanezumab 5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.","primaryOutcome":{"measure":"Percentage of Participants With Adjudicated Primary Composite Joint Safety Outcome","timeFrame":"Baseline up to Week 80","effectByArm":[{"arm":"Tanezumab 2.5 mg","deltaMin":3.9,"sd":null},{"arm":"Tanezumab 5 mg","deltaMin":7.1,"sd":null},{"arm":"NSAID","deltaMin":1.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0123"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":30},"locations":{"siteCount":507,"countries":["United States","Australia","Brazil","Bulgaria","Colombia","Croatia","Japan","Lithuania","Mexico","New Zealand","Peru","Philippines","Russia","Serbia","Slovakia","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":["38650049","38343426","37652258","37470295","36474952","36301512","35980115","35960482","35351194","35232805","35217440","33538113"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091058&StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%2C%20Active-controlled%2C%20Multicenter%20Study%20Of%20The%20Long-term%20Safety%20And%20Efficacy%20Of%20Subcutaneous%20Administration%20Of%20Tanezumab%20In%20Subjects%20With%20Osteoarthritis%20Of%20The%20Hip%20Or%20Knee"]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":1002},"commonTop":["Arthralgia","Nasopharyngitis","Fall","Upper respiratory tract infection","Headache"]}}